Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity ...
Renal & Urology News

Genomic Prostate Score Identifies Indolent Biology Among Higher-Risk Prostate Cancers

The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs ...
Seeking Alpha

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
Labiotech.eu

Six biotech companies advancing the next generation of prostate cancer therapies

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Seeking Alpha

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic ...

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...
Nasdaq

INmune Bio's INKmune Receives Veteran Participation In Prostate Cancer Trial

(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage biotechnology company focused on immunotherapy treatments, announced Tuesday the expansion of its ongoing Phase I/II trial to include veterans ...
Business Wire

Nanostics and Protean BioDiagnostics Partner to Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the United States

CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...
Business Wire

Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...
NBC4 Columbus

Deep Bio & Techcyte Partner to Integrate AI-Powered Prostate Diagnostics & Frozen Section on Techcyte Fusion® Platform

OREM, UT, UNITED STATES, August 26, 2025 /EINPresswire.com/ -- Deep Bio, a global leader in AI-powered cancer diagnostics, today announced a strategic partnership ...
KXAN

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- ...
BioTechniques

Targeting prostate cancer’s Achilles’ heel

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for new and more effective treatments. An international team has uncovered two ...
BioWorld

RNA panel detects and differentiates prostate cancer from benign prostate hyperplasia

Prostate cancer is still one of the main causes of cancer death among men; while prostate-specific antigen (PSA) testing is done for screening, there are recommendations against its use due to its ...